Intas Allays Concerns Around Lucentis Biosimilar In India
Executive Summary
Intas Pharmaceuticals has claimed that certain adverse events reported with its Lucentis biosimilar were not caused by “qualitative aspects” of the product and that physicians have since “very satisfactorily” used subsequent batches of the vascular endothelial growth factor inhibitor in India.
You may also be interested in...
Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
Mylan Eylea Biosimilar Gets Green Signal For Trials In India
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
Intas Launches First Biosimilar Lucentis, In India
India’s Intas is working on a well-thought out strategy for its newly launched Razumab, the first biosimilar version of Lucentis anywhere in the world. The plan is to ride lower costs to beat the innovator’s drug and also penetrate a market that is widely dependent on the off-label use of Avastin to treat wet age-related macular degeneration.